Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA May Impose More "522" Studies As Post-Approval Enforcement Tool

Aug 31 2009

Related Content

Cyberonics Q1 Epilepsy Sales Up 16%; Firm Continues To Ramp Up R&D Spend

Aug 24 2009

FDA Expects Draft Document On Post-Approval Study Design By September

Jun 29 2009

Additional Topics

More from Archive

More from Medtech Insight

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window